Loading
companiesCompany
Imugene
Imugene is an Australian company now focused on an off-the-shelf CAR-T cell therapy made from donor cells for people with blood cancers that have come back after other treatments.
Overview
Imugene Limited, headquartered in Sydney and listed on the ASX, describes itself as a clinical-stage cell therapy company developing off-the-shelf cancer treatments. Its lead programme azer-cel (azercabtagene zapreleucel) is an allogeneic CD19-directed CAR-T therapy in a phase 1/1b open-label study in relapsed or refractory non-Hodgkin lymphoma and B cell acute lymphoblastic leukaemia, recruiting in Australia and the United States. The company previously developed oncolytic virus (VAXINIA / CF33, onCARlytics) and B cell vaccine (HER-Vaxx, PD1-Vaxx) programmes, but these are not described on the current website, which centres on azer-cel. No capital raising could be sourced from fetched pages.
Notes
top- ASX code IMU (IMU.AX) not confirmed on fetched pages, so ticker omitted. Oncolytic virus and vaccine programmes not visible on the current site; companyType set to cell-therapy to match the current lead. dlbcl used as the closest id for relapsed or refractory non-Hodgkin lymphoma.
Similar pages
- CompanyCellogen Therapeutics
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
- PersonJae H. Park
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- CompanyPoseida Therapeutics
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- PersonWaseem Qasim
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- TrialCAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Shares CD19, Acute lymphoblastic leukaemia.
- CompanyCaribou Biosciences
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- CompanyAllotera Therapeutics (formerly Wugen)
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia.